These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22592129)

  • 1. Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: a need for more mechanistic studies and large, randomized, placebo-controlled trials.
    Foo JP; Mantzoros CS
    Metabolism; 2012 Oct; 61(10):1331-6. PubMed ID: 22592129
    [No Abstract]   [Full Text] [Related]  

  • 2. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome.
    Sekhar RV; Jahoor F; Iyer D; Guthikonda A; Paranilam J; Elhaj F; Coraza I; Balasubramanyam A
    Metabolism; 2012 Oct; 61(10):1395-403. PubMed ID: 22542724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipokines in the HIV/HAART-associated lipodystrophy syndrome.
    Paruthi J; Gill N; Mantzoros CS
    Metabolism; 2013 Sep; 62(9):1199-205. PubMed ID: 23706880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin in congenital and HIV-associated lipodystrophy.
    Tsoukas MA; Farr OM; Mantzoros CS
    Metabolism; 2015 Jan; 64(1):47-59. PubMed ID: 25267014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
    Koutkia P; Canavan B; Breu J; Torriani M; Kissko J; Grinspoon S
    JAMA; 2004 Jul; 292(2):210-8. PubMed ID: 15249570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
    Sivakumar T; Mechanic O; Fehmie DA; Paul B
    HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?
    Mantzoros CS
    Endocr Pract; 2010; 16(2):162-6. PubMed ID: 20350904
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.
    Hu M; Tomlinson B
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1143-50. PubMed ID: 20872317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptin and insulin resistance: good, bad, or still unclear?
    Oral EA; Burant C
    Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E394-5, author reply E396. PubMed ID: 19171843
    [No Abstract]   [Full Text] [Related]  

  • 11. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?
    Mantzoros CS
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1089-91. PubMed ID: 19349474
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effects of Leptin Replacement on Neural Plasticity.
    Paz-Filho GJ
    Neural Plast; 2016; 2016():8528934. PubMed ID: 26881138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy.
    Paz-Filho G; Mastronardi C; Delibasi T; Wong ML; Licinio J
    Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):690-7. PubMed ID: 21340154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Control and treatment of HIV-associated lipodystrophy syndrome and related metabolic complications].
    Hansen BR; Haugaard SB; Nielsen JO; Madsbad S; Iversen J; Andersen O
    Ugeskr Laeger; 2003 Oct; 165(44):4218-20. PubMed ID: 14621554
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome.
    Verkauskiene R; Dollfus C; Levine M; Faye A; Deghmoun S; Houang M; Chevenne D; Bresson JL; Blanche S; Lévy-Marchal C
    Pediatr Res; 2006 Aug; 60(2):225-30. PubMed ID: 16864709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
    Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic therapy for HIV-associated lipodystrophy.
    Benavides S; Nahata MC
    Ann Pharmacother; 2004 Mar; 38(3):448-57. PubMed ID: 14755064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of leptin therapy in metabolic dysfunction.
    Park JY; Gavrilova O; Gorden P
    Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.